The use of radioisotopes for palliation of metastatic bone pain.
Bone pain associated with advanced prostate and other cancers is a frequent and significant complication. Pharmaceutical therapy of bone pain includes nonsteroidal analgesics and opiates. While external beam radiation therapy remains the mainstay of pain palliation of solitary lesions, bone-seeking radiopharmaceuticals have entered the armamentarium for the treatment of multiple osseous metastases. The 3 radioisotopes currently approved for treatment of pain (strontium-89/(89)Sr, samarium-153/(153)Sm and rhenium-186/(186)Re) are discussed in this review including the approved dose, method of administration and indications for use.
Gkialas
I
I
Department of Urology, General Hospital of Athens G. Gennimatas, 154 Mesogeion Avenue, Athens, Greece. igkialas@ath.forthnet.gr
Iordanidou
L
L
Galanakis
I
I
Giannopoulos
S
S
D001859:Bone Neoplasms / Q000532:radiotherapy* / Q000556:secondary*; D006801:Humans; D009369:Neoplasms / Q000150:complications* / Q000473:pathology / Q000628:therapy; D010146:Pain / Q000209:etiology* / Q000532:radiotherapy*; D010166:Palliative Care / Q000379:methods*; D011868:Radioisotopes / Q000627:therapeutic use*; D019275:Radiopharmaceuticals / Q000627:therapeutic use*
D011868:Radioisotopes; D019275:Radiopharmaceuticals